FDAsafety guidance72% confidence
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Merck.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · PD-1 Inhibitor
- Sub-indication
- General
Related signal: Merck's Pembrolizumab Study Targets Japanese Pediatric and Adult Cancer Patients